Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Hidradenitis Suppurativa
About this trial
This is an interventional treatment trial for Hidradenitis Suppurativa
Eligibility Criteria
Inclusion Criteria:
- Age > 13 years old.
- Subject must voluntarily sign and date an informed consent, approved by an independent ethics committee / institutional review board.
- Subject is willing to comply with the procedures in this protocol.
- The subject must be diagnosed with HS and receiving care at HSC
- Subjects with Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) score between 2 and 5
- The subject must have an inflamed nodule or abscess at the time of enrollment.
Exclusion Criteria:
- The subject has an HS-PGA score of 0 or 1
- The subject has received ILTAC less than 8 days prior to the initial visit.
- The subject does not have capacity to consent to the study.
- The subject is has taken systemic steroids at least 4 weeks prior to the time of enrollment.
- The subject has a known allergy or history of adverse reaction to steroids.
- The subject is pregnant.
- Subjects who have received a biologic therapy two weeks before and during the study period.
Sites / Locations
- Steven Cohen
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Active Comparator
Experimental
Experimental
Sodium Chloride 0.9%
Intralesional Triamcinolone 10 mg/mL
Intralesional Triamcinolone 20 mg/mL
Intralesional Triamcinolone 40 mg/mL
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of sodium chloride 0.9% in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.
Each active hidradenitis suppurativa lesion will be injected with up to 1 mL of intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas. The maximum treatment volume is 3 mL.